JP4642242B2 - 細胞接着の阻害剤としての新規のグアニジン誘導体 - Google Patents

細胞接着の阻害剤としての新規のグアニジン誘導体 Download PDF

Info

Publication number
JP4642242B2
JP4642242B2 JP2000598485A JP2000598485A JP4642242B2 JP 4642242 B2 JP4642242 B2 JP 4642242B2 JP 2000598485 A JP2000598485 A JP 2000598485A JP 2000598485 A JP2000598485 A JP 2000598485A JP 4642242 B2 JP4642242 B2 JP 4642242B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
cycloalkyl
formula
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000598485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002536438A5 (enExample
JP2002536438A (ja
Inventor
ペイマン アヌシルヴァン
クノル ヨッヘン
ショイネマン カールハインツ
ウィリアム ウィル デイビッド
カルニアトー ドニ
グールベスト ジャンフランソワ
ガデック トマス
キャサリン ボダリー セイラ
Original Assignee
アヴェンティス ファルマ ドイチェラント ゲーエムベーハー
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴェンティス ファルマ ドイチェラント ゲーエムベーハー, ジェネンテック， インコーポレイテッド filed Critical アヴェンティス ファルマ ドイチェラント ゲーエムベーハー
Publication of JP2002536438A publication Critical patent/JP2002536438A/ja
Publication of JP2002536438A5 publication Critical patent/JP2002536438A5/ja
Application granted granted Critical
Publication of JP4642242B2 publication Critical patent/JP4642242B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2000598485A 1999-02-13 2000-02-04 細胞接着の阻害剤としての新規のグアニジン誘導体 Expired - Lifetime JP4642242B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99102916A EP1028114A1 (en) 1999-02-13 1999-02-13 Novel guanidine derivatives as inhibitors of cell adhesion
EP99102916.6 1999-02-13
PCT/EP2000/000895 WO2000047564A1 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Publications (3)

Publication Number Publication Date
JP2002536438A JP2002536438A (ja) 2002-10-29
JP2002536438A5 JP2002536438A5 (enExample) 2007-01-11
JP4642242B2 true JP4642242B2 (ja) 2011-03-02

Family

ID=8237555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000598485A Expired - Lifetime JP4642242B2 (ja) 1999-02-13 2000-02-04 細胞接着の阻害剤としての新規のグアニジン誘導体

Country Status (11)

Country Link
US (1) US6340679B1 (enExample)
EP (2) EP1028114A1 (enExample)
JP (1) JP4642242B2 (enExample)
AT (1) ATE273285T1 (enExample)
AU (1) AU768206B2 (enExample)
CA (1) CA2371789C (enExample)
DE (1) DE60012890T2 (enExample)
ES (1) ES2225086T3 (enExample)
IL (1) IL144725A0 (enExample)
MX (1) MXPA01008072A (enExample)
WO (1) WO2000047564A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
JP2003506491A (ja) 1999-08-13 2003-02-18 バイオジェン インコーポレイテッド 細胞接着インヒビター
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
DK1682537T3 (da) * 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
ES2530780T3 (es) * 2005-05-17 2015-03-05 Sarcode Bioscience Inc Composiciones y métodos para el tratamiento de trastornos oculares
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
CA3105972A1 (en) * 2007-10-19 2009-04-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
JP2011521896A (ja) * 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0673247A4 (en) 1992-12-01 1996-05-01 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS.
ATE227567T1 (de) 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
AU702661B2 (en) 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU726793B2 (en) 1995-08-14 2000-11-23 Scripps Research Institute, The Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
SK176898A3 (en) * 1996-06-28 1999-05-07 Merck Patent Gmbh Phenylalamine derivatives as integrin inhibitors
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
SK10632000A3 (sk) 1998-01-23 2001-02-12 Aventis Pharma Deutschland Gmbh Sulfónamidové deriváty ako inhibítory resorpcie kostí a inhibítory bunkovej adhézie

Also Published As

Publication number Publication date
EP1028114A1 (en) 2000-08-16
ES2225086T3 (es) 2005-03-16
ATE273285T1 (de) 2004-08-15
WO2000047564A1 (en) 2000-08-17
EP1155003B1 (en) 2004-08-11
AU768206B2 (en) 2003-12-04
IL144725A0 (en) 2002-06-30
DE60012890T2 (de) 2005-08-25
CA2371789C (en) 2009-04-14
AU2669900A (en) 2000-08-29
EP1155003A1 (en) 2001-11-21
JP2002536438A (ja) 2002-10-29
MXPA01008072A (es) 2002-07-30
CA2371789A1 (en) 2000-08-17
US6340679B1 (en) 2002-01-22
DE60012890D1 (de) 2004-09-16

Similar Documents

Publication Publication Date Title
JP4642242B2 (ja) 細胞接着の阻害剤としての新規のグアニジン誘導体
KR20010033281A (ko) 골흡수 억제제 및 비트로넥틴 수용체 길항제인 신규 아실구아니딘 유도체
US6747148B2 (en) Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6660728B2 (en) Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
JP2002501054A (ja) 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
US6747016B1 (en) Substituted purine derivatives as inhibitors of cell adhesion
US6762190B2 (en) Thienylalanine derivatives as inhibitors of cell adhesion
JP4550286B2 (ja) 新規なアシルグアニジン誘導体、それらの製造方法、薬剤としてのそれらの使用及びそれらを含有する製薬組成物
US6838453B2 (en) Antagonist derivatives of the vitronectin receptor
JP4522586B2 (ja) 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用
JP2003532732A5 (enExample)
US7259159B2 (en) Guanidino derivatives as inhibitors of cell adhesion
CZ20002246A3 (cs) Derivát acylguanidinu jako inhibitor resorpce kostí jako antagonist vitronektinového receptoru
CZ20002672A3 (cs) Sulfonamidové deriváty jako inhibitory kostní resorpce a jako inhibitory buněčné adheze

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100618

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101201

R150 Certificate of patent or registration of utility model

Ref document number: 4642242

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term